Dr. Zhigang Tian’s laboratory is credited with seminal discoveries regarding basic knowledge and clinical study of natural killer (NK) cells, particularly liver-resident NK cells, cytokine-producing NK cells, and NK cell-based immunotherapy. Since outstanding contributions in the field of NK cell research, Dr. Tian was elected as a member of the Chinese Academy of Engineering in 2017. Dr. Tian used to work as a visiting scientist in NCI/NIH, USA during 194-1996 and in Kanazawa University, Japan during 2002-2003. Currently, he is a professor at University of Science and Technology of China (USTC) in Hefei, China, where he also works as a Director of Institute of Immunology, Director of The Key Lab of Innate Immunity and Chronic Diseases of Chinese Academy of Science, and President of Medical Center, and the former dean of School of Life Sciences of USTC. Dr. Tian is the current President of Chinese Society of Immunology (CSI) and Council member of International Union of Immunological Societies (IUIS) and Federation of Immunological Societies of Asia-Oceania (FIMSA), and a co-Editor-in-Chief of Cell Mol Immunol, an official journal of CSI, and editorial board members of up to ten journals including Hepatology, J Autoimmune, Eu J Immunol and J Biol Chem, and has published more than 300 papers in peer-reviewed journals including Cell, Nat Immunol, Immunity, Cell Metabolism, J Exp Med, J Clin Invest, Nat Commun, PNAS, Gastroenterology, Hepatology, etc.

Dr. Chengcheng Zhang, Morton H. Sanger Professorship in Oncology and Michael L. Rosenberg Scholar for Biomedical Research at University of Texas Southwestern Medical Center, earned his B.S. degree from the Special Class for the Gifted Young and Department of Biology of University of Science and Technology of China in 1992 and his Ph.D. in Biochemistry from the University of Illinois at Urbana-Champaign in 1999. He received his postdoctoral training under the mentorship of Drs. Harvey Lodish and Robert Weinberg at Whitehead Institute/MIT. Dr. Zhang established his independent lab at UT Southwestern Medical Center in 2007. He is studying the function of immune surface molecules on stem cells and cancer, focusing on how cancer and stem cells gain immune privilege and regulate their cell fates and metabolism through interaction with the immune system. His research aims to develop novel therapies for cancer treatment. Since 2007, He received 30 research grants as a Principle Investigator from sources including NIH, DOD, CPRIT, with a total of $27 million direct cost. He published more than 90 peer-reviewed publications in hematopoietic stem cell and cancer research fields, including senior author publications in Nature, Nature Medicine, Nature Cell Biology, Nature Immunology, Cell Stem Cell, and Blood. He was a recipient of a number of awards, including American Society of Hematology Junior Faculty Scholar Award, Leukemia & Lymphoma Society Scholar Award, and Royan International Research Award. In addition, he is enthusiastic about translational research, with a number of IPs licensed by the pharmaceutical industry. Furthermore, he trained 23 postdoctoral researchers, 18 graduate and undergraduate students, and 6 research technologists. Several of his postdoc trainees are now tenure-track assistant professors or professors at University of Texas, University of Missouri-Columbia， University of the Ryukyus, Fudan University, and Shanghai Jiao Tong University.

Dr. Gill obtained his medical degree and Ph.D in immunology from the University of Melbourne in Australia, and a post-doctoral fellowship in cellular therapy at Stanford University. Dr. Gill is now an assistant professor of medicine at the University of Pennsylvania where he specializes in the treatment of patients with leukemia and in bone marrow transplantation. He has led clinical trials of chimeric antigen receptor (CAR) T cell trials for chronic and acute leukemias. Dr. Gill’s research laboratory focuses on the interface between adoptive cellular therapy and genetic engineering.

Jean-Pierre Latere (Chief Operating Officer) joined Celyad in January 2016 and is responsible for strengthening the organization and key processes in manufacturing, quality, program management and regulatory affairs. He started his career as a Research Associate at the Michigan State University in the US. Following that assignment, he moved to the Johnson & Johnson group where he held various positions, from Scientist to Senior Scientist. He then joined Cardio3 BioSciences in 2008 as Project Manager Delivery System and left the company in 2012 in the position of Senior Director Business Development. Prior to joining Celyad, Jean-Pierre served as Beauty Care and Healthcare Market Global Leader at Dow Corning. Jean-Pierre holds a PhD in Chemistry from the University of Liège, Belgium.

Chunming Rao, Professor, second-level professional and technical post, received bachelor degree of science from Xiamen University, majoring in biochemistry in 1983, and became an employee in the Division of Biochemistry, NICPBP. In 1993 he was appointed to be vice director of Division of Biochemistry, in 2000 to be Professor, NICPBP, in 2003 to be director of Division of Biochemistry & Genetic Engineering, NICPBP, and in 2010 to be director of Division of Recombinant Biological Products, IBPC, NIFDC. He additional post executive member of Pharmacopoeia Committee, the chairman of Professional Committee on General Principles of Biological Products, member of State New Drug Evaluation Committee, etc., and has been devoting himself to the research of biotech drugs’ quality control for over 30 years and established the quality control technology system for biotech drugs from scratch in NIFDC. He has participated in more than 20 national and provincial research projects on quality control of biotech drugs, published 225 research papers and 11 technical monographs as a co-writer, got 8 patents, and successfully formulated the national quality criteria of biotech drugs, some of which have been embodied in Chinese Pharmacopoeia.

Researcher, Cell Laboratory, Institute of Biological Products Verification, China Institute of Food and Drug Verification, is mainly engaged in quality control of biological products. In recent years, it has undertaken or participated in a number of national projects, covering the fields of cell matrix, immunocytotherapy, tissue engineering cells and stem cells, focusing on cell quality control methods and quality standards. He is currently a national expert in new drug review, member of the 11th National Pharmacopoeia, member of the National and Beijing Stem Cell Clinical Research Committee, etc.

Shuren Zhang was born in 49 years, is a researcher, doctoral supervisor and director of the department of immunology；institute of oncology, cancer hospital, Chinese academy of medical sciences. In 82-83, he was invited as a visiting scholar of NIH and NCI. He is mainly engaged in the research of tumor immune mechanism and biological therapy. In 1992, the state council issued a special government allowance. He has participated in the ministry of health and the state food and drug administration to develop somatic cell and gene therapy application for clinical research related documents; In 2017, he won the outstanding scholar award of the Chinese society of immunization.

Dr. Xin Du (杜新) is a regulatory professional with unique combination of FDA and industry regulatory experience as well as international regulation knowledge and experience. He obtained his Ph.D degree from the University of Florida and completed his post-doctoral training at the National Institute of Health (NIH). He worked for US FDA, and pharmaceutical companies of Aventis-Pastuer, Wyeth, Novartis, BMS, NPS, Actinium and Advaxis. Currently, he is the Senior VP of Regulatory and Quality at Adlai Nortye USA Inc.

Deputy Director of National Cancer Center; Vice-President of Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) & PUMC; Deputy Director of National GCP Center for Anti-Cancer Drug Clinical Trials; Director of Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; Director of academic department of China anti-cancer association(CACA); President of Chinese Association of Clinical Oncologists (CACO); Chairman of the anti-tumor drug committee of China pharmaceutical association. Prof. Shi was awarded the first class prize of national science and technology progress award, several provincial and ministerial science and technology progress awards and national invention patents.

Dr. Xiaoqiang Yan is Chief Scientific Officer in Generon Biomed Ltd. He plays a leading role in developing Generon’s product pipeline and technology platforms. He has served in this position since 2010. He was Vice President of research at Hutchison Medipharma Ltd. Shanghai, China, from 2005 to 2009 and he joined the company as a senior director in 2002 established new drug discovery platforms in oncology and autoimmune diseases. From 1995 to 2002, he was a biologist and research scientist at Amgen Inc. Thousand Oaks, California, USA at department of at the departments of Experimental Hematology, Pathology and Pharmacology and Functional Genomics. His research work was focused on hematology, oncology, immunology, endocrinology, and bone biology. He joined Amgen in 1993 as a postdoctoral fellow in the department of Experimental Hematology. He obtained his Ph.D. in molecular and cell biology at the Department of Medical Biophysics, University of Toronto, Canada. He obtained his Bachelor of Medicine, and Master of Medicine from West China University of Medical Science, Chengdu, Sichuan Province, China. In recent years, he is focused on developing novel immune therapies to treat cancer patients.

Director, PI and doctoral supervisor at Department of Molecular Oncology, Eastern Hepatobiliary Surgery Hospital of the Second Military Medical University and National Liver Cancer Center. Editorial board member of Cancer Letters, associate editor of Chinese Journal of Metastatic Oncology. Majoring in R&D of oncolytic adenovirus and tumor biological targeted therapy, research of tumorigenesis mechanism and intervention. It has undertaken 12 major national science and technology special projects, including the major new drug innovation projects, national key research and development projects, and national natural science foundation projects.

Wang Zhiming, the CEO of Tasly (Tianjin) BioPharmaceutical Co., Ltd., which focuses on innovative gene therapy and oncolytic virus products development. He hosted the CMC development of two innovative therapeutic biologics, and leaded the non-clinical research, RA and clinical development of the two biologics. He has more than 10 years work experience in biologics period, covering preclinical, RA, clinical development, industrialization and commercialization production.

YujiaCai, male, Ph. D., studied at Shandong University, Chinese Academy of Sciences, and Carolinska Medical College. He received his Ph. D. from Aarhus University in Denmark in 2014. He joined Shanghai Jiao Tong University in 2017. He has been engaged in the research and development of gene therapy virus vectors, gene editing and delivery technology, as well as the interaction between gene therapy vectors and the immune system of the organism for a long time, and has devoted himself to the clinical transformation of bench-to-bedside. Patented techniques for lentivirus protein and RNA transduction have been developed. In the past five years, relevant papers have been published in eLIFE, NAR, Gene Therapy, Current Gene Therapy, JCI, EMBO J and other journals. The research project is funded by Shanghai Natural Fund, Pu Jiang Talents and Shanghai Health Planning Commission Collaborative Innovation Cluster.

Founder of Xiamen NKD Biotechnology Co., Ltd., visiting scholar of Michigan State University, doctor of chemical biology of Xiamen University. Long-term commitment to biomedical research, has a senior research in the field of new drug research and development in glycochemistry.

Dr. Guoyu Pan, received his PhD in China Pharmaceutical University in 2003. He joined Novartis Institute of Biomedical Research (NIBR) as Head of Mechanistic Lab in 2007. In 2011, Guoyu joined Shanghai Institute of Materia medica (SIMM). His research interests focus on liver alternative model and cell therapy. As founder of Hexaell Biotech, Inc, Guoyu is working on the pipeline to help patients with severe liver diseases, especially liver failure. His bioartificial liver project was supported by “The key programs for Science and Technology development of China” in 2018.

Dr. Jinhua Lu, is the co-founder and currently serves as the chief scientific officer of TriArm Therapeutics Co., Ltd. Prior to his current position, he worked for nine years in the Office of Tissues and Advanced Therapies, CBER, US FDA. As an expert preclinical reviewer he has reviewed regulatory submissions related to medical devices, cell and gene therapies, and combinatory products, with a specialty in immunotherapies, stem cell therapies and therapeutic vaccines. He has experience of reviewing submissions from pre-pre-IND stage to BLA. In addition to his review work, he also served in scientific committees and working groups, participated in writing guidance documents, teaching courses and involved in other outreach activities. Prior to joining FDA, Dr. Lu worked in biotech industry as a senior scientist, manager and consultant developing various viral vectors for cancer treatment, and vaccines for viral diseases. He has experience in strategic planning, project management, process and assay development, formulation and regulatory compliance. He obtained his Ph.D. in microbiology/immunology from US Uniformed Services University of Science and Health and completed his post-doctoral training in CBER, FDA, working on the pathogenesis of viral hepatitis.

Dr. Mingjun Wang，Executive President of Shenzhen Institute for Innovation and Translational Medicine, received his MD from Anhui Medical University, China and his PhD degree from the University of Copenhagen, Denmark. The focus of Dr. Wang’s research is to investigate how to effectively utilize the human immune system to control and eliminate cancer cells and translate the scientific findings from the bench to the clinic. Currently，he is focusing on T cell-based cancer immunotherapy using TIL, TCR-T cells or CAR-T cells. Dr. Mingjun Wang has published nearly 30 peer-reviewed papers and three book chapters in the field of cancer immunology.

Dr. Guo-Liang Yu is the global CEO of Apollomics Inc. (Formerly CBT Pharmaceuticals), an innovative therapeutics company devoted to curing cancer by combining immunology and other caner fighting methods. Before Apollomics Inc., Dr. Yu was the Executive Chairman of Crown Biosicence Inc., a publically-listed personalized oncology platform company with ~600 employees globally. Crown Bioscience was acquired by JSR for $400 million in May of 2018. He co-founded Epitomics Inc., an antibody biotechnology company, and served as Chairman and CEO for 10 years prior to its acquisition by Abcam for $170 million. He was also a venture partner at OrbiMed Venture LLC. Dr. Yu’s success is driven by his scientific curiosity and passion for translating scientific discovery to real products. After graduating from Fudan University in Shanghai, China, he came to the United States in 1984 to pursue advanced studies. He obtained his Ph.D. from UC Berkeley, where he and Dr. Greider discovered telomerase and its mechanism in Dr. Blackburn’s lab. Drs. Blackburn and Greider received Nobel Prize in 2009 for their discovery. Dr. Yu later joined Dr. Frederick Ausubel’s lab at Harvard University to pursue the question of how plants defend themselves against pathogens without an immune system, and identified the plant disease resistance gene. In 1993, when genomics was still in its infancy, Dr. Yu joined Human Genome Sciences Inc. as one of the first few senior scientists, identifying human gene targets for drug discovery. Among several important drug targets he studied was BLys, the first successfully genomic target for the development of a lupus antibody drug Benlysta, which was approved by FDA in 2010. In 1998, Dr. Yu was attracted to identifying plant genes with economic value in agriculture and in bio-energy. He was Senior Vice President of R&D at Mendel Biotechnology Inc. where his team analyzed the function of a complete set of plant transcription factors, and ultimately identified several valuable traits such as enhanced crop yield, disease resistance, and drought tolerance. Dr. Yu has co-authored 43 peer-reviewed scientific articles that have been referenced by the scientific community over 6000 times. He is a co-inventor of more than 400 patents. Dr. Yu is the founding president of the Chinese Biopharmaceutical Association (CBA) and serves on the boards of several professional organizations in the United States and China, including BayHelix, Chinese-American Bio/Pharmaceutical Society (CABS), National Foundation of Cancer Research, Ray Wu Memorial Foundation, and University of Pacific. Dr. Yu is generous in coaching young entrepreneurs, and he has co-founded a dozen startup companies in biotech and the healthcare sector, including Immune-Onc Therapeutics, Inc.in Palo Alto.

Dr. Dong Wei is the CEO of EdiGene. He has over 20 years of experience in innovative drug development and management. He had led more than 10 clinical-stage programs in multinational companies. The programs were involved in cancer, Alzheimer’s disease, neurodegenerative diseases, metabolic diseases, autoimmune diseases, and genetic diseases. He also worked in Deloitte Consulting as Senior Consultant and Manager for Strategic and Operational Consulting, advising over 10 healthcare and life science multinational clients.

He has been engaged in biopharmaceuticals for more than 30 years. He has been in charge of vaccine production, scientific research and development, GMP quality management and major project construction in Wuhan Institute of Biological Products. As a visiting scholar, he went to German Cancer Research Center and Heidelberg University to study molecular virology, cooperated in the study of hepatocellular carcinoma and anti-oncogene P53, and established a screening system for anti-hepatitis B virus drugs. One of the leaders of the project of measles and mumps vaccine, established the preparation technology of mumps vaccine, completed pre-clinical and clinical research, and obtained the production approval number through the national new drug review in 2004. In 2003, the Ministry of Science and Technology of China, the Hubei Science and Technology Department and the Wuhan Science and Technology Bureau undertook 863 emergency SARS research projects. The "intravenous human SARS immunoglobulin" was approved for emergency use. The Ministry of Science and Technology entrusted the Hubei Science and Technology Department to organize expert identification to reach the international leading level. The inactivated SARS vaccine completed pre-clinical research. At present, he is deputy general manager of Wuhan Binhui Biotechnology Co., Ltd. and is responsible for GMP quality management. OH2 injection of oncolytic virus has completed pre-clinical research and is about to carry out clinical research.

Dr. Lu received his doctor's degree in clinical medicine (hematology) in 2006. He has seven years'experience as a clinical doctor. Before 2007, Dr. Lu mainly engaged in clinical and scientific research of hematopoietic stem cells and mesenchymal stem cells. In 2001, he participated in the completion of the first umbilical cord blood transplantation for the treatment of childhood leukemia in China. In 2004, he established the separation technology of umbilical cord mesenchymal stem cells for the first time in China. In 2005, he went to Westchester Medical Center of New York Medical College of the United States to continue to work on hematopoietic cell transplantation and mesenchymal stem cell research. Several papers were published in international and domestic Dr. Lu joined multinational pharmaceutical companies in 2007 and has been engaged in research and development of innovative drugs and strategic planning for new products in the field of blood and cancer for more than 10 years. He has worked in key positions of multinational companies such as Novartis, Jianzan, Roche, AstraZeneca and Merceton. He has rich research and development in targeted drugs, immunotherapy and cell therapy. Experience in product life cycle management. It plays an important role in the registration, R&D and market expansion of epoch-making cancer products such as Gleevey, Herceptin, Teresa and Coreda. In June 2018, Dr. Lu left the multinational pharmaceutical enterprises and joined the ranks of domestic innovative drug research and development. Now as CEO of Heyuan Biotechnology (Tianjin) Co., Ltd., we are committed to promoting the progress of basic and clinical research of cell therapy in China, promoting the industrialization process of cell therapy, building the leading cell therapy products in the world and saving the lives of blood and cancer patients.

Dr. Leicester University, specialist of National Thousand People Program, leader of Guangdong Province, president and CSO of Guangdong Xiangxue Precision Medical Technology Co., Ltd., researcher of Infection and Immunity Center of Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, and part-time researcher of National Key Laboratory of Respiratory Disease Research. Li Yi has been engaged in antibodies and T cell receptors for a long time in Britain. Pharmaceutical research and development, the main papers published in Nature Biotechnology, Nature Medicine, JBC, Molecular Cancer Therapy and other patents, and has been invited to the United Kingdom, Germany, the United States, Ireland for many times to hold lectures, and as the backbone of the EC 7th Framework Project to participate in the development of treatment of type I diabetes mellitus. And biological drugs. Li Yi is a scientist who studied directed molecular evolution earlier. He pioneered the application of phage display technology in directed evolution of T cell receptor (TCR). He developed the first human high affinity soluble TCR in the world, which increased the affinity of TCR to recognize pHLA by more than one million times. 05) This is the TCR collar. Key breakthroughs in the domain. He has successfully developed a number of highly affinity TCRs for FDA-approved clinical immunotherapy research products by leading team of Immunocore in the UK. As a specialist of the National Thousand Persons Program, Li Yi returned home in 2012 full-time to carry out multi-faceted basic and applied immunotherapy research, and led the establishment of China's first high affinity TCR-mediated T-cell therapy platform. The first specific TCR-T product TAEST16001 injection developed by its Xiangxue team has been approved by the National Drug Administration (NMPA) for the first clinical trial of TCR-T drugs (IND).

Dr. David Shao is the President and CEO of Yisheng Biopharma. Yisheng Biopharma is a globally focused biopharmaceutical company discovering, developing and commercializing innovative immunological biologics with operations in China, the United States, Singapore and certain Southeast Asian countries. Dr. Shao has over 20 years of experience in healthcare investment, capital market and healthcare industry. He was a Principal Scientist focusing on oncology and metabolic disease research at Roche Pharma, USA, a Senior Healthcare Analyst and investment manager at Mehta Partners and Kamunting Street Capital in New York City. Dr. Shao received his Ph.D. at University of California, San Diego and MBA at Stern School of Business (Y2003) in New York University. Her is also a chartered CFA and AICPA in the US.

The vice president of Shanghai Cell Therapy Group/general manager of drug transformation system is mainly engaged in drug transformation of cell therapy products, and carries out drug transformation research and registration declaration of the first domestic non-viral vector CAR-T products.

Dr. Zhao received his BS, MS, and MD (all majored in Oncology) from Xi’an Jiaotong University Health Science Center. He was a practicing oncologist in Xi’An, China from 1997-2007. In 2008 joined BMS in its clinical affairs department and since then has assumed increasing responsibilities as a clinical trial expert at Beijing H&J CRO International (Vice President and Director of Clinical Center), Shanghai Rundo CRO (Director of Clinical Center) ,3D-HTS (Vice President),Osmunda (Executive Vice General Manager and Director of Clinical Center)

Graduated from Emory University, Atlanta, Georgia, in 1990, with PhD in Biochemistry and Molecular Biology. Worked in biomedical research and pharmaceutical drug discovery since 1990, with long term focus on cancer biology, immuno-oncology, antibody engineering technology and cancer drug discovery, as well as mitochondrial energy metabolism and apoptosis, and work experience with Tanox and Pfizer (La Jolla Lab). Fruitful in the field of research pursued, with many publications as first author or corresponding author in scientific magazines such as Cell, Journal of Biochemistry, Cancer Immunology and Immunotherapy, Journal of Cell Biology. Registered and granted with over 20 patented inventions worldwide.

Dr. Zhang is the co-founder, president and CEO of AEON(Beijing) a joint venture between Eureka Therapeutics Inc. and Zhongyuan Concorde Cell Gene Engineering Co., Ltd. (SH: 600645). Prior to the establishment of Yiang Biology, Dr. Zhang Yu served as assistant president and senior strategic planning expert of Zhongyuan Concorde Cell Gene Engineering Co., Ltd. (SH: 600645). Dr. Zhang received a bachelor's and master's degree in biomedical engineering from Beijing University of Aeronautics and Astronautics, and a doctor's degree in stem cell and regenerative medicine from Heinrich-Heine-Universit t Dyusseldorf University in Heinrich, Germany. During his stay in Germany, he served as a director of the Rhine Forum in Germany, a lecturer at the Rhine University of Science and Technology in Bonn, Germany, a visiting scholar at the Helmholtz Center of the German Space Agency and the University of Palermo in Italy. Dr. Zhang is a member of the German Stem Cell Society, the Chinese Society of Cell Biology and a reviewer of Current Stem Cell Research & Therapy magazines. Selected 131 talents plan, the first batch of Tianjin Green Card winners.

Feifei Qi, Ph.D. is the CTO and co-founder of Immunochina Pharmaceuticals, developing best-in-class genetically engineered cell products for oncology indications, where he oversees the CMC activities for all next generation immune cell therapies. He received his Ph.D. in Biology at School of Life Sciences, Tsinghua University in 2015. He has over 10 years of research experience in cancer immunotherapy, and 5 years of experience in process development and quality analysis for cell & gene therapy products.

Dr. Wenqi Hu is the vice president of Beijing Mabworks Biotech Ltd, taking overall responsibility of innovative therapeutic antibody discovery. From2001 to 2013, Dr. Hu was vice president of Suzhou Mabspace Biopharmaceutical Inc., Sr. Director of Protein Science and Antibody Discovery of Crown Biosciences Inc., Sr. Scientist of Verenium Corporation (now a part BASF), and Sr. Scientist and Sr. Investigator of Merck Research Laboratory (MRL). Dr. Hu has extensive experience in innovative antibody discovery from target selection and validation, antibody characterization and engineering, to preclinical studies. Dr. Hu is the inventor of several immune check-point inhibitors (e.g., CLDN18.2, OX40, CD40 etc.) and MGCD290, a first-in-class HOS2 inhibitor under phase 2 clinical trials in the US and Canada.

Male, Doctor of Medicine, Histology and Embryology, Tongji Medical College, Huazhong University of Science and Technology. In 2018, it was awarded the title of "Labor Model of Hubei Province" by the Hubei Federation of Trade Unions. He has been engaged in teaching and scientific research for many years in universities and served as the executive director of Hubei Biochemical Society and Molecular Biology Society. He is good at industrializing high-tech achievements in biology. In September 2010, Dr. Cai set up Wuhan Bwd Biotech Biotechnology Co., Ltd. and began to devote himself to the research of virus and anti-cancer. On January 21, 2015, Dr. Cai won a patent for the invention of a coxsackievirus and its application of anti-cancer drugs. In the same year, Dr. Cai obtained the eighth batch of 3551 talents from Wuhan Dong Hu Hi-tech Co., Ltd.

Dr. Weiyue Gu, received his Ph.D from Nankai University of Biophysics. He is the founder and CEO for both of the companies: Beijing Chigene Ltd., and Beijing Chineo Ltd. He was the champion of 2015 Innovation Medical Entrepreneurship competition and the Zhongguancun Entrepreneurship winner; He has been involving the leading and developing of tumor whole exon and ctDNA based gene sequencing. Dr. Gu collaborated with scholars from University of Pennsylvania on developing of CAR-T , TCR-T and several other types of cell therapy. He believes that "diagnosis and treatment should be integrated" in tumor's treatment. Dr. Gu is also the pioneer in exploring and developing on personalized neoantigen/TIL-based cancer cell therapy. He is an executive director of the precision medicine branch of China medical promotion association for birth defects; Dr. Gu leads several innovative projects related to precision medicine and birth defects. He is the author of the book "Precision Diagnosis in Genetic Disease".

Dr. Zhang liang graduated from Shanghai Institute of Biochemistry and Cell Biology, CAS. He used to be the project leader of drug research and development in Shanghai Haiyan Medical Technology CO. LTD. (Yangtze River Pharmaceutical Group). Currently, he is responsible for the development and production of cell therapy as the vice president of BIORAY LABORATORIES Inc. He has rich experience in new drug development, compliance and application, he also has extensive experience in cell therapy technology and translational systems development.

Dr. Victor Li has 25 years experience in biopharmaceutical industry and 4 years experience in clinical medicine. He founded his first biotechnology company and successfully transferred the company after completing phase I/II clinical trials of two vaccine products. As co-founder and director of several biotechnology companies in Singapore, such as Lion TCR, BioCheetah and ImmuNOA, SCG Cell and BioSyngen, they are start-up biotechnology companies separated from Singapore A*Star and Munich University of Technology (TUM). Their business is focused on immune T cell cancer treatment and concomitant diagnosis. Prior to that, he worked at PricewaterhouseCoopers in management consulting for the medical biotechnology industry and Ciba-Geigy Pharmaceutical.

Graduated from the Department of Bioscience and Technology, Tsinghua University in 2009. He received his Ph.D. degree from National University of Singapore in 2015. In October 2014, he joined Singapore Request Biotechnology Co., Ltd. as head of China. In July 2016, we jointly founded Suzhou Creek Gene Biotechnology Co., Ltd. as the chief operating officer, responsible for the company's operation management and business development, while fully managing the diagnostic products department.

Dr. Glover主要负责Pall的生物技术细胞和基因治疗业务。此前，他负责GE Healthcare的细胞疗法产品开发工作，并在Stemcell Technologies担任营销和产品管理职位。Clive拥有不列颠哥伦比亚大学遗传学博士学位。

Chenyan Wu graduated from Xiamen University in 1986 and received his M.S. degree from Shanghai Institute of Biochemistry, Chinese Academy of Science in 1992. In 1993 he received a fellowship as a graduate student at State University of New York at Buffalo and received his Ph.D. degree in 1998. After one year of postdoctoral training at Harvard University, he joined Pfizer Global Research and Development in 1999 and became a drug hunter. He founded TheraMab Bioscience Inc. in 2013.

In the mid-1990s, Dr. Lai Shoupeng carried out postdoctoral research on cancer immunotherapy in Steven Rosenburg Laboratory, Director of Surgery, National Cancer Institute of the United States. After entering the biomedical industry, he has been engaged in research and development of new biological drugs for more than 20 years. He has accumulated rich experience in biopharmaceutical technology development, GMP production and project management. In 2014, Nanjing leadsbiolabs Co., Ltd. was co-founded, focusing on the development of new anti-cancer drugs for immunotherapy.

1989年毕业于同济医科大学，1994年获得同济医科大学外科肿瘤学硕士学位，2005年获得加拿大麦克马斯特大学（McMaster University）分子免疫学博士学位。曾在美国斯坦福大学医学院肿瘤中心以及美国仙灵宝雅生物制药（Schering-Plough Biopharma）从事博士后研究工作；曾任中美冠科生物技术有限公司（Crown Bioscience Inc.）免疫学总监，辉瑞-冠科亚洲肿瘤研发中心执行总监。共发表学术论文30余篇, 申请专利50余项。周博士的主要研究兴趣在于建立肿瘤个体化诊断和治疗平台，研发具有自主知识产权的肿瘤靶点和免疫靶点的多功能抗体类药物。这类抗体能够同时结合肿瘤细胞以及人体免疫细胞，协同激活机体抗肿瘤和免疫机制，有效的增强药物对肿瘤细胞的清除能力。

Xiao Jieqiong has ten years of experience in the field of biopharmaceuticals. She is currently the technical director of Gibco cell culture product line in the Bio-industry Department of ThermoFisher Scientific. She leads the Gibco cell culture technology team to provide solutions in the fields of cell therapy, gene therapy, antibodies and vaccines that meet the requirements of technology and regulations. In 2012, he received a master's degree in cell biology from Xiamen University and participated in the process development of recombinant HPV vaccine and the preparation of various HPV pseudoviruses.

Zhiyu works as the marketing manager of biopharma in GE healthcare life sciences, joined GE healthcare in April,2011 and held several positions in the life sciences. Including downstream filtration and purification technical support, process development and application expert, senior bioprocess resins modality, Lab PD platform, vaccine and gene therapy solutions manager, in the biological products industry has more than 10years of experience.

He is currently working in oobio (Shanghai) Co., Ltd. (New Third Board Stock Code 839702), as Deputy General Manager. He is mainly responsible for gene therapy and cell therapy virus vector technology research and development, technology amplification, clinical project declaration, and clinical GMP virus production. At present, more than 2000 square meters of viral product development and pilot-scale GMP-Like platform have been built for pre-clinical process development and technology amplification assessment, and 5000 square meters of a full-time technical GMP workshop for providing three batches of clinical declaration samples and clinical I/II research samples. Products include plasmids, lentiviruses, adenoviruses, adeno-associated viruses, poxvirus, herpes virus. During GE's tenure as Director of Research and Development of Life Sciences, more than 20 pilot projects have been completed, the CRO/CDMO service model of GE in China has been established, and two pilot production platforms for monoclonal antibodies of GE in China have been established. In 2015, the field verification of pre-clinical trial production of CFDA has been carried out. With many years of practical experience in the process management of biopharmaceutical R&D, he has been responsible for or participated in the construction and trial operation of several world-class GMP production workshops and bases. His specialty areas include the development of cell culture and drug purification processes, the development and validation of analytical methods, technology transfer, pre-clinical pilot production and operation, and so on. Animal experiments, CFDA clinical declaration and late clinical research, and in-depth research and rich experimental experience in disposable production technology, process validation, experimental design DOE, high-throughput process development and project management. Dr. Jia has published 8 papers, including 6 SCI papers and 2 CFDA drug regulatory works. He is the chairman of the Biological Committee of the International Pharmaceutical Engineering Association (ISPE) and chairman of the Biopharmaceutical Technology Department.

Henry Li, CSO – Oncology, Inflammation and Immunology Since joining Crown in 2011, Dr. Li has been a key architect of our world class Translational Oncology platform. Before joining CrownBio, Dr. Li has over 20 years of biopharmaceutical, as well as academic R&D, experience in cancer and viral infection, including leadership roles as R&D Director/Senior Director in several US-based biotech companies. Dr. Li currently holds visiting Professor position at Peking University-State Key Laboratory. Dr. Li earned his Ph.D. in Molecular Biology/Biochemistry from the University of California (Irvine) and completed his postdoctoral training at UCLA School of Medicine. He has published more than 60 manuscripts and edited 3 books in the biopharmaceutical areas. He is also on the editorial board of Current Signal Transduction Therapy.

Siying Peng, Ph.D., Postdoc. of Institute of Immunology Affiliated to Harvard Medical School, and president of BEIJING IDMO CO., LTD. Dr. Peng is devoted to the research and application of humanized mouse models in the field of tumor immunotherapy. She had won as ‘Beijing New-star Plan of Science and Technology ’,‘The sea poly project of Beijing overseas talents Beijing Overseas Talents Gathering Program’, and was appointed as ‘Distinguished Expert in Beijing’.

Tan Chang, Director of Ph.D Shanghai Jikai Gene Project In 2002, he graduated from College of Life Sciences, Zhongshan University, Department of Biochemistry, Bachelor's degree. In 2008, he graduated from the College of Life Sciences, Fudan University, majoring in Biochemistry and Molecular Biology, Ph.D. During his Ph.D. study, he mainly carried out RNA interference, hepatitis B virus and cancer-related research. After graduation, he joined the enterprise work and served as the research manager of scientific research projects such as Shanghai Science and Technology Commission Fund, Shanghai Small and Medium-sized Enterprises Innovation Fund, National 11th Five-Year Plan Major Infectious Disease Prevention and Control Project, 863 Program Major Project and so on. He has rich cancer target gene screening and research, virus vector development and preparation, etc. Experience. He also served as product manager and market manager. In 2018, Jikai Gene established an independent cell-gene therapy CDMO/CMO project group.

Xingu Zhong got his Ph.D. degree in Fudan University and join BD company as the senior technical expert in the life science department, responsible for the technical and application support of single-cell multi-omics platform. Xingyu Zhong’s researchmainly focus on genome mining and cancer metabolism, especially the Warburg effect. He was involved in key research project of Ministry of Science and Technology of china and National Natural Science Foundation of China.He published papers about cancer metabolism and genome mining incell reports and science china life sciences, now he is focusing on single cell sequencing application in cancer, immunology, and development.

Ten years of pre-clinical CMC development experience in biotechnology has rich experience in process development and scale-up production. Manage and participate in 8 biopharmaceutical projects. As the head of the first project, he has completed the development of the commissioned new biological drug project, KLT-1101, a national class of anti-cancer, whole blood picture recovery drug, and completed its complex process and quality control standards. He has successfully passed on-site verification and obtained CFDA clinical experimental approval in a very short period of time. Since 2017, a clinical CMC development platform for Car-T cell therapeutic transfection plasmids has been established, and the CMC Development Research of plasmid part in the first Car-T declaration of CFDA has been completed and declared, and the clinical trial approval has been successfully obtained. Over the past years, project management has accumulated rich pre-clinical CMC development experience.

Li Runrun, graduated from the School of Pharmacy, Peking University Medical Department, master of chemical biology, and dual degree in economics, Beida National Development Research Institute. He is currently working in the Investment Promotion Center of the Management Committee of Taizhou Pharmaceutical Hi-tech Industrial Park and serves as Deputy Director-General of the Third Bureau of the Investment Promotion Center.